12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Medivir, J&J sales and marketing update

Johnson & Johnson launched simeprevir to treat chronic HCV genotype 1 infection as Olysio in the U.S., as Galexos in Canada and as Sovriad in Japan. In the U.S., Olysio has a wholesale acquisition cost of...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >